Medicinal cannabis in the pediatric population

Cannabinoids during pregnancy can cross the placental barrier and affect neurodevelopment since prenatal exposure to cannabis has been associated with hyperactivity, impulsivity and attention difficulties in childhood. The effects of cannabinoid toxicity can be more pronounced in children than in adults.

In children, the use of marijuana in small doses can cause ataxia, drowsiness, lethargy, altered mental status and drowsiness. Pediatric patients rarely have more severe adverse effects, such as apnea, cyanosis, bradycardia, hypotonia, and opisthotonos. Currently the strongest evidence is for the treatment of refractory epilepsy (Dravet and Lenox Gastou syndrome) with the pure cannabinoid Cannabidiol - CBD- without traces of other cannabinoids and it is very limited for developmental disorders in children (autism, deficit disorder attention and hyperactivity) from series of cases or isolated cases; and that have gained popularity in social networks, and there is also an increased risk of accidental exposure, due to the availability of different forms of cannabinoids.

Cannabis medicine and pregnancy

During pregnancy, it is not recommended to receive medical cannabis, as they cross the placental barrier and can affect the baby. Neither in the lactation stage, because cannabinoids are excreted in breast milk.

Cannabis medicine and driving

If the patient is receiving medical cannabis, where 9 - Tetrahydrocannabinol (Δ9-THC), you should be careful when driving the first days and only do it later if you do not have signs or symptoms that prevent it (drowsiness, decreased reflexes, etc.) You must also carry the medical formula in case it is required by an authority.